INCIDENCE OF TUMOURS OF THE SKELETON IN 224-RA TREATED ANKYLOSING SPONDYLITIS PATIENTS
We are following 1426 ankylosing spondylitis (a. sp.) patients treated with 224-Ra and 1556 control patients with a. sp. not treated with any form of ionizing radiation. The average follow-up time of the exposure group is 16 years, the average alpha dose to the skeleton is 65 rad, resulting fron intraveneous injection of 4.8/uCi/kg 224-Ra on average within a medium injection span of 12 weeks. Injections normally have been performed once a week, in some cases also half-weekly with a correspondingly shorter injection span. Since 1970 three cases of malignant tumours in the skeleton have been observed in the exposure group in patients with skeletal alpha doses below 90 rad compared with 0.6 expected. No bone tumour occurred until now in the control group. Two of the three cases were tumours of the bone marrow. The incidence of leukaemias in both, exposure and control group is discussed with respect to phenylbutazone treatment and alpha radiation from 224-Ra. An effect of 224-Ra on the bone marrow not yet detected in the SPIESS series of patients treated with higher amounts of 224-Ra cannot be excluded.
Bibliographic Reference: INTERNATIONAL SYMPOSIUM ON THE BIOLOGICAL EFFECTS OF LOW-LEVEL RADIATION WITH SPECIAL REGARD TO STOCHASTIC AND NON-STOCHASTIC EFFECTS, VENEZIA (ITALY), APRIL 11-15, 1983 AVAILABILITY: CEC LUXEMBOURG, DG XIII/A2 MENTIONING PAPER E 31123 ORA
Availability: Can be ordered online
Record Number: 1989122003100 / Last updated on: 1987-01-01
Available languages: en